Ukraine Help: The heroes of Mainz-Finthen
Travis Kelley helps Olena and Wasyl flee from Ukraine. This is the record of a dramatic and emotional rescue operation.
Search
Boehringer Ingelheim Ruminant Well-Being Awards 2020
The World Association for Buiatrics and Boehringer Ingelheim announce the Ruminant Well-Being Awards.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
A career at the intersection of science and marketing
A member of the Animal Health digital marketing team, our colleague Missy talks about her purpose to bring transformative technologies to the vet community
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Tackling NCDs through innovation AND collaboration
Non-communicable diseases are a significant medical, humanitarian and socio-economic issue. Rapid innovation and holistic approaches help us tackle them
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
U.S. FDA grants priority review for spesolimab in GPP
U.S. FDA grants priority review for spesolimab in the treatment of patients with generalized pustular psoriasis
cystic fibrosis phase II trial
The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Human Health Partnering
Human Health Partnering
Overcoming heartworm disease for homeless pets
Heartworm-free pets soar to new lives. Together with our Greater Good Charity partners, our colleagues helped bring shelter dogs to forever homes.
EMPRISE-Study
EMPRISE-Study
Life forward - Boehringer Ingelheim company brand
Life forward - Boehringer Ingelheim unveils its evolved company brand
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Lady, a guide dog in the office
A great partnership between a Boehringer Ingelheim employee and her guide dog at work. Their relationship goes beyond the human-animal bond.
Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD
FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive Phenotype
How fast can a cheetah run wild and free?
Cheetahs’ top speed can reach up to 120km/h. But habitat loss, illegal wildlife trade and hunting made these impressive animals critically endangered.
BI X colleague about working with purpose
Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
Dogs at work in Milan offices
Dogs at work is a pilot project that allows pet-lover to bring their dogs to the office and enjoy the benefits they bring to their daily work life.
Central Nervous System Diseases
Find out more about our research and development in central nervous system diseases
Schizophrenia in real life
Discover the reality of life with schizophrenia through the stories of people who are breaking down the stigma of living with a serious mental illness.
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.